Academic Journal
Προβολή σε EDS

Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker Investigation.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker Investigation.
Συγγραφείς: Abdshah A; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Alyamani M; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Burgess RA; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Parekh DJ; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Spieler B; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA., Singal R; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Abramowitz MC; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA., Merchan JR; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Medicine, Medical Oncology Division, University of Miami Miller School of Medicine, Miami, Florida, USA., Pannunzio L; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Mahal BA; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA., Kobetz E; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA.; Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA., Punnen S; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Bilusic M; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA., Sharifi N; Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Πηγή: The Prostate [Prostate] 2026 May; Vol. 86 (7), pp. 771-783. Date of Electronic Publication: 2026 Feb 23.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8101368 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0045 (Electronic) Linking ISSN: 02704137 NLM ISO Abbreviation: Prostate Subsets: MEDLINE
Imprint Name(s): Publication: <2005-> : Hoboken, NJ : Wiley-Liss
Original Publication: New York : Alan R. Liss, c1980-
Ιατρικοί όροι (MeSH): Saliva*/metabolism , Saliva*/chemistry , Metabolomics*/methods , Prostatic Neoplasms*/metabolism , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/blood , Biomarkers, Tumor*/blood , Biomarkers, Tumor*/metabolism, Biomarkers/blood ; Biomarkers/metabolism ; Androgen Antagonists/therapeutic use ; Hydrocortisone/metabolism ; Humans ; Male ; Pilot Projects ; Aged ; Middle Aged ; Community-Based Participatory Research
Περίληψη: Introduction: Using serum metabolomics in Community-Based Participatory Research (CBPR) with underserved populations presents challenges due to the invasive nature of venipuncture, which limits longitudinal sample collection in community settings. In this pilot study, we compared saliva and serum metabolomics in patients with prostate cancer to evaluate saliva's potential in biomarker research and identified metabolic changes associated with androgen deprivation therapy (ADT).
Methods: Blood and saliva were collected from 20 eugonadal patients with prostate cancer and 20 patients receiving ADT. Untargeted metabolomics of metabolites was performed, and glucocorticoids were quantified using targeted metabolomics. Data were analyzed using MassHunter, METLIN database, and MetaboAnalyst.
Results: Across all samples, 1198 metabolites were identified. Comparing ADT to eugonadal serum and integrating fold change (FC > 2 or FC < 0.5) and significance (adjusted p < 0.1), we identified 14 upregulated and 20 downregulated metabolites. Comparing ADT to eugonadal saliva, we identified 14 upregulated and 28 downregulated metabolites. Targeted metabolomics confirmed correlations between serum and salivary cortisol and salivary and serum cortisone (r = 0.61 and 0.62, p < 0.001), underscoring the potential of saliva glucocorticoids as biomarkers for stress-related metabolic alterations and suggesting that saliva reflects the systemic metabolomic profile.
Conclusion: ADT-associated metabolomic changes are detectable in saliva. Targeted analysis suggests that salivary glucocorticoids may serve as biomarkers of metabolism and stress in community-based studies. Our findings support saliva as a non-invasive alternative to serum for biomarker research, facilitating community-based investigations and advancing public health efforts.
(© 2026 The Author(s). The Prostate published by Wiley Periodicals LLC.)
References: Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):887-906. (PMID: 27197278)
Cancer Med. 2020 Jun;9(11):3691-3702. (PMID: 32232974)
Cancer Health Disparities. 2020;4:. (PMID: 35252767)
J Breath Res. 2018 Apr 04;12(3):036009. (PMID: 29528036)
Ann Oncol. 2020 Mar;31(3):369-376. (PMID: 32057540)
Mol Cancer Res. 2021 Mar;19(3):475-484. (PMID: 33168599)
Anal Bioanal Chem. 2012 Jun;403(6):1523-48. (PMID: 22576654)
Metabolites. 2020 Jan 26;10(2):. (PMID: 31991929)
Front Endocrinol (Lausanne). 2019 Jul 17;10:479. (PMID: 31379745)
Diagnostics (Basel). 2019 Feb 19;9(1):. (PMID: 30791464)
Nat Rev Urol. 2020 Sep;17(9):526-539. (PMID: 32694594)
Elife. 2017 Feb 13;6:. (PMID: 28191869)
J Clin Epidemiol. 2012 Mar;65(3):301-8. (PMID: 22169081)
Best Pract Res Clin Endocrinol Metab. 2013 Dec;27(6):795-801. (PMID: 24275191)
J Steroid Biochem Mol Biol. 2016 Oct;163:103-12. (PMID: 27108942)
Clin Chem Lab Med. 2017 Aug 28;55(9):1315-1323. (PMID: 28076306)
Endocrinology. 1994 Dec;135(6):2533-41. (PMID: 7988441)
Horm Behav. 2012 Aug;62(3):295-313. (PMID: 22841799)
Cancer Treat Rev. 2024 Mar;124:102697. (PMID: 38401478)
J Lipid Res. 2008 May;49(5):1137-46. (PMID: 18281723)
Korean J Urol. 2011 Feb;52(2):79-89. (PMID: 21379423)
Cancers (Basel). 2017 Feb 08;9(2):. (PMID: 28208703)
Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):240-6. (PMID: 20404727)
Nat Rev Urol. 2016 Jan;13(1):47-60. (PMID: 26643568)
BMC Cancer. 2025 Jan 7;25(1):29. (PMID: 39773200)
Med Oncol. 2017 Jan;34(1):7. (PMID: 27943101)
Korean J Urol. 2015 Jan;56(1):12-8. (PMID: 25598932)
Clin Endocrinol (Oxf). 2011 Mar;74(3):289-93. (PMID: 21092052)
Prostate. 2026 May;86(7):771-783. (PMID: 41728749)
Cancers (Basel). 2024 Mar 19;16(6):. (PMID: 38539538)
J Clin Endocrinol Metab. 1996 Sep;81(9):3244-8. (PMID: 8784076)
Clin Biochem. 2008 Jun;41(9):688-92. (PMID: 18280810)
J Urol. 2010 Nov;184(5):1971-6. (PMID: 20884032)
J Oncol Pract. 2018 Oct;14(10):580-587. (PMID: 30312560)
Sci Rep. 2018 Oct 10;8(1):15063. (PMID: 30305646)
Clin Microbiol Rev. 2013 Oct;26(4):781-91. (PMID: 24092855)
J Clin Endocrinol Metab. 2010 Nov;95(11):4951-8. (PMID: 20685855)
Dig Dis Sci. 2025 May;70(5):1616-1624. (PMID: 39516436)
Int J Urol. 2018 Jan;25(1):45-53. (PMID: 29052905)
Eur Urol. 2014 Mar;65(3):642-9. (PMID: 23428068)
J Clin Oncol. 2021 Dec 20;39(36):4061-4068. (PMID: 34597119)
Health Educ Res. 2020 Dec 23;35(6):627-636. (PMID: 33025021)
BMC Urol. 2020 Jun 19;20(1):71. (PMID: 32560654)
Int J Mol Sci. 2023 Nov 22;24(23):. (PMID: 38068926)
Grant Information: R01CA172382 United States NH NIH HHS; R01CA261995 United States NH NIH HHS
Contributed Indexing: Keywords: androgen deprivation therapy; metabolomic profiling; non‐invasive biomarkers; saliva‐serum comparison; systemic metabolism
Substance Nomenclature: 0 (Biomarkers, Tumor)
0 (Biomarkers)
0 (Androgen Antagonists)
WI4X0X7BPJ (Hydrocortisone)
Entry Date(s): Date Created: 20260223 Date Completed: 20260708 Latest Revision: 20260813
Update Code: 20260813
PubMed Central ID: PMC13077258
DOI: 10.1002/pros.70144
PMID: 41728749
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1097-0045
DOI:10.1002/pros.70144